Living Homeopathy International, a Hong Kong-based company selling homeopathic products, has withdrawn its plans for an initial public offering in the United States. The company had most recently planned to raise approximately $19 million, making the withdrawal another setback for a smaller international issuer seeking access to U.S. public markets.
Company Background
Living Homeopathy International sells homeopathic products in Hong Kong. The company was founded in 1994, giving it more than three decades of operating history in the market.
However, the information provided does not disclose detailed financial results, product categories, revenue figures, growth rates or the company’s broader expansion strategy. The available filing information therefore provides limited visibility into the underlying business beyond its focus on homeopathic products in Hong Kong.
IPO Details
Living Homeopathy International initially filed for its U.S. IPO in May 2025. The company subsequently revised its proposed offering in March 2026, planning to raise approximately $19 million by offering 3.8 million shares at a price range of $4 to $6.
The company had planned to list on the Nasdaq under the symbol LHI. Revere Securities was expected to serve as the sole bookrunner.
The company ultimately withdrew its IPO plans on Tuesday, meaning the proposed offering will not proceed under the terms previously filed.
Market Context & Opportunities
The planned Nasdaq listing would have provided Living Homeopathy International with access to U.S. public markets while potentially increasing its visibility among international investors.
For smaller companies based outside the United States, a Nasdaq listing can provide access to a broader investor base and a public trading platform. However, the available information does not identify specific market expansion plans or strategic initiatives that Living Homeopathy International intended to fund with the proposed $19 million offering.
The withdrawal therefore leaves the company’s future financing and public-market strategy unclear based on the information provided.
Risks & Challenges
The withdrawal itself highlights the challenges smaller international companies can face when attempting to access the U.S. IPO market. Market conditions, investor demand, valuation expectations and the costs associated with becoming a publicly traded company can all influence whether an offering ultimately proceeds.
Living Homeopathy International also operates within the homeopathic products market, but the available information does not provide sufficient detail to assess its competitive position, regulatory environment or profitability.
Without a completed offering, investors will not receive the expected public-market disclosure associated with an IPO, while the company will also forgo the approximately $19 million in proceeds it had sought to raise.
Outlook
Living Homeopathy International’s decision to withdraw its proposed $19 million U.S. IPO underscores the selective nature of the public markets for smaller international issuers. After initially filing in 2025 and revising its offering terms in 2026, the company ultimately chose not to proceed with its planned Nasdaq listing.
For now, the next steps for Living Homeopathy International remain unclear. The withdrawal does not necessarily eliminate the possibility of a future public offering, but any renewed attempt would likely depend on the company’s financing needs and prevailing market conditions.
